#United States #San Diego #Aethlon Medical #Hemopurifier #cancer trial

Aethlon Medical’s Third Quarter Update: Financial Results and Clinical Trials Progress

Progress in Clinical Trials

Aethlon Medical, Inc. (Nasdaq: AEMD), a company focused on developing innovative therapies for cancer and infectious diseases, recently announced its financial results for the fiscal third quarter, which ended on December 31, 2024. The company is making strides in its Hemopurifier cancer trial underway in Australia, with significant milestones reached, including the treatment of the first patient. The patient enrolled in the trial was treated at Royal Adelaide Hospital on January 29, 2025, marking a major milestone in their ongoing efforts to assess the safety and efficacy of the Hemopurifier in patients whose solid tumors have not responded to anti-PD-1 therapies.

Clinical Trials Details

During this quarter, Aethlon reported steady progress in their oncology trial involving the Hemopurifier. Three patients have been enrolled to date. Unfortunately, two patients did not proceed to treatment due to pre-defined stopping criteria; one of them showed a response to anti-PD-1 therapy, while the other experienced toxicity associated with the therapy. The third patient, who was unresponsive to the anti-PD-1 drug, successfully underwent a four-hour treatment with the Hemopurifier. Initial assessments from this trial will analyze extracellular vesicle removal and the impacts on anti-tumor T-cell activity. However, final results await all three patients' treatments to be completed.

In response to feedback from investigators, Aethlon has swiftly amended its trial protocols. Notably, patients will now be considered for enrollment only after confirming they do not respond to anti-PD-1 therapy, streamlining the identification process and minimizing delays. These adjustments also expand eligibility criteria to include a broad spectrum of schedules for Pembrolizumab and Nivolumab dosages.

Operational Efficiency Initiatives

In addition to trial advancements, Aethlon Medical has proactively worked on cutting operational costs, achieving a significant 50% reduction in consolidated operating expenses for the quarter. This was driven by a reduction of $1.3 million in payroll due to headcount cuts and has better positioned the company to focus on its high-impact oncology trials. Management emphasizes that these initiatives are vital to sustain resources and support continued clinical progress, particularly in Australia and India, where a similar trial is planned.

Financial Insights

Financially, Aethlon reported a cash balance of approximately $4.8 million at the end of December 2024. The operational cost savings led to a net loss reduction to around $1.8 million, down from $3.5 million during the same period last year, demonstrating effective management during challenging economic circumstances. The changes in operational strategy and cost structures not only eased financial strain but also enabled resource allocation that aligns with future trial ambitions.

Future Directions

Looking ahead, Aethlon maintains ambitions to expand its Hemopurifier trial, with ongoing discussions surrounding protocol applications in India. They have obtained ethics committee approval at Medanta Medicity Hospital and await further clearance from the country’s regulatory agency. Though navigating regulatory challenges may introduce delays, Aethlon’s focus remains steadfast on the ultimate goal of propelling its clinical programs forward.

Conclusion

In summary, Aethlon Medical is navigating the complexities of conducting clinical trials while tightening its fiscal management. The initial success of the Hemopurifier in treating the first patient in Australia is significant, and the company is optimistic about future enrollments under the amended protocols. As Aethlon moves forward, its commitment to innovation in cancer treatment remains strong, providing hope for patients facing life-threatening conditions.